XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.25.1

AGREEMENT WITH KWANGDONG | 9 Months Ended
--- | ---
Mar. 31, 2025
AGREEMENT WITH KWANGDONG |
AGREEMENT WITH KWANGDONG | (8) AGREEMENT WITH KWANGDONG On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (“Kwangdong”) for exclusive rights to commercialize Vyleesi in Korea (the “Kwangdong License Agreement”). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea which has not occurred as of March 31, 2025.

X
- References No definition available. + Details
Name: | ptn_AgreementWithKwangdongAbstract
Namespace Prefix: | ptn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ptn_AgreementWithKwangdongTextBlock
Namespace Prefix: | ptn_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration